ClinicalTrialsFinder

Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma Clinical Trials in Boston, Massachusetts

1 recruitingBoston, Massachusetts

Showing 1–1 of 1 trials

Recruiting
Phase 2Phase 3

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

Oropharyngeal p16INK4a-Negative Squamous Cell CarcinomaStage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7+6 more
National Cancer Institute (NCI)613 enrolled341 locationsNCT01810913